Fidelity Investments’s Neuropace NPCE Stock Holding History
Bought
Maintained
Sold
Other funds holding NPCE
PCH
SCM
FLAM
O
DCM
AC
Fidelity Investments's NPCE Position: Q2 2026 in Review
Fidelity Investments increased its Neuropace (NPCE) stake by 0.22% in Q2 2026, buying an estimated $20K and bringing the position to 554,771 shares worth $8.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2186.
Fidelity Investments first reported a position in NPCE in Q2 2021 and has held it in 21 quarters since. The position peaked at $25.2M in Q2 2021. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.
- Fidelity Investments held 554,771 shares of Neuropace worth $8.82M as of Q2 2026.
- Fidelity Investments bought 1,242 Neuropace shares in Q2 2026, an estimated $20K.
- Neuropace made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2186 holding.
- Fidelity Investments first reported a position in Neuropace in Q2 2021 and has held it in 21 quarters since.
- Fidelity Investments's Neuropace position peaked at $25.2M in Q2 2021.
- 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.